about 80%, about 90%, about 95%, or about 100% following administration of one or more doses of the formulation to the patient.

[0044] In another embodiment, one or more signs or symptoms are reduced in severity or duration by about 2-fold, about 5-fold, about 10-fold, about 15-fold, about 20-fold, about 25-fold, about 30-fold, about 35-fold, about 40-fold, about 45-fold, about 50-fold, about 55-fold, about 60-fold, about 65-fold, about 70-fold, about 75-fold, about 80-fold, about 90-fold, about 95-fold, about 100-fold, or more, following administration of one or more doses of the formulation to the patient.

[0045] Provided herein is a method of treating an ophthalmologic condition in a patient in need thereof, comprising administering to said patient a formulation described herein, whereby one or more signs or symptoms of said ophthalmologic condition are ameliorated by the treatment. Administration of the formulation may be intravitreal administration.

[0046] Also provided herein is a method of preventing or treating a cancer or metastasis in a subject in need thereof, comprising administering to said patient a formulation described herein, whereby one or more signs or symptoms of said cancer or metastasis are ameliorated. Administration of the formulation may be intravenous administration.

[0047] In the methods provided herein, a subject to be treated can be a human or a non-human subject. Formulations provided herein can be administered once or multiple times depending on the health of the patient, the progression of the disease or condition, and the efficacy of the treatment. Adjustments to therapy and treatments can be made throughout the course of treatment (*e.g.*, the dosage of an antibody in a composition).

[0048] In one embodiment, there is provided use of a formulation comprising from about 1 mg/ml to about 150 mg/ml of an anti-CD105 antibody, or antigen-binding fragment thereof, up to about 100 nM buffering agent, up to about 1 M polyol, and a pH of about 4.0 to about 7.5, in the manufacture of a medicament for treating an angiogenesis-related disease in a subject in need thereof.

[0048a] In one embodiment, there is provided use of a formulation comprising from about 1 mg/ml to about 150 mg/ml of an anti-CD105 antibody, or antigen-binding fragment thereof, up to about 100 nM buffering agent, up to about 1 M polyol, and a pH of about 4.0 to about 7.5, and optionally a surfactant, whereby one or more signs or symptoms of said ophthalmologic condition are ameliorated, in the manufacture of a medicament for treating an ophthalmologic condition in a patient in need thereof.

[0048b] In one embodiment, there is provided use of a formulation comprising from about 1 mg/ml to about 150 mg/ml of an anti-CD105 antibody, or antigen-binding fragment thereof, up to about 100 nM buffering agent, up to about 1 M polyol, and a pH of about 4.0 to about 7.5,

whereby one or more signs or symptoms of said cancer or metastasis are ameliorated, in the manufacture of a medicament for preventing or treating cancer or metastasis in a subject in need thereof.

[0048c] Provided herein is a method of monitoring the efficacy of one or more of any of the methods provided herein. Levels of soluble CD105 have been correlated with survival in cancer patients and can be monitored prior to and during therapy. Levels of soluble CD105 can, therefore, be one indication that a therapeutic regimen is effective in treating the patient. Treatments described herein may include one or more additional treatments.

INCORPORATION BY REFERENCE

[0049] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

[0050] The novel features of the embodiments are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present embodiments may be obtained by reference to the following detailed description that sets forth illustrative

33. ~~A method of treating an angiogenesis-related disease in a subject in need thereof, comprising administering to said patient~~ Use of a formulation comprising from about 1 mg/ml to about 150 mg/ml of an anti-CD105 antibody, or antigen-binding fragment thereof, up to about 100 mM buffering agent, up to about 1 M polyol, and a pH of about 4.0 to about 7.5, in the manufacture of a medicament for treating an angiogenesis-related disease in a subject in need thereof.

34. The ~~method~~ use of claim 33, wherein said anti-CD105 antibody comprises a light chain variable region (V_L) having an amino acid sequence set forth as SEQ ID NO: 1; a light chain constant region (C_L) having an amino acid sequence set forth as SEQ ID NO: 2; a heavy chain variable region (V_H) having an amino acid sequence set forth as SEQ ID NO: 3; and a constant region (Fc) having an amino acid sequence set forth as SEQ ID NO: 4.

35. The ~~method~~ use of claim 33, wherein said anti-CD105 antibody comprises a V_L CDR1 having an amino acid sequence set forth as SEQ ID NO: 5; a V_L CDR2 having an amino acid sequence set forth as SEQ ID NO: 6; a V_L CDR3 having an amino acid sequence set forth as SEQ ID NO: 7; a V_H CDR1 having an amino acid sequence set forth as SEQ ID NO: 8; a V_H CDR2 having an amino acid sequence set forth as SEQ ID NO: 9; and a V_H CDR3 having an amino acid sequence set forth as SEQ ID NO: 10.

36. The ~~method~~ use of claim 33, comprising about 25 mg/ml anti-CD105 antibody or, antigen-binding fragment thereof.

37. The ~~method~~ use of claim 33, comprising about 50 mg/ml anti-CD105 antibody or, antigen-binding fragment thereof.

38. The ~~method~~ use of claim 33, comprising about 100 mg/ml anti-CD105 antibody or, antigen-binding fragment thereof.

39. The ~~method~~ use of claim 33, wherein said formulation comprises less than 300 mM polyol and the formulation is made isotonic with a salt.

40. The ~~method~~ use of claim 33, wherein said buffering agent is histidine or acetate.

41. The ~~method~~ use of claim 40, comprising about 20 mM histidine or acetate.

42. The ~~method~~ use of claim 33, wherein the polyol is a sugar.

43. The ~~method~~ use of claim 42, wherein the sugar is a non-reducing sugar.

44. The ~~method~~ use of claim 43, wherein the non-reducing sugar is trehalose or sucrose.

45. The ~~method~~ use of claim 44, comprising about 240 mM trehalose or sucrose.

46. The ~~method~~ use of claim 42, wherein the sugar is sorbitol.

47. The ~~method~~ use of claim 46, comprising about 240 mM sorbitol.

48. The ~~method~~ use of claim 33, wherein said formulation is administered intravitreally or intravenously.

49. The ~~method~~ use of claim 33, further comprising a surfactant.

50. The ~~method~~ use of claim 49, wherein the surfactant is polysorbate 20, polysorbate 80 or Pluronic® F68.

51. The ~~method~~ use of claim 33, wherein the angiogenesis-related disease is a cancer, or a metastasis.

52. The ~~method~~ use of claim 51, wherein the cancer is a solid tumor.

53. The ~~method~~ use of claim 51, wherein the cancer is an epithelial based tumor.

54. The ~~method~~ use of claim 51, wherein the cancer is a lung cancer, a gynecologic malignancy, a melanoma, a breast cancer, a pancreatic cancer, an ovarian cancer, a uterine cancer, a colorectal cancer, a prostate cancer, a kidney cancer, a head cancer, a pancreatic cancer, a liver cancer (hepatocellular cancer), a uterine cancer, a neck cancer, a kidney cancer (renal cell cancer), a sarcoma, a myeloma, a brain cancer, or a lymphoma.

55. The ~~method~~ use of claim 33, wherein said angiogenesis-related disease is an ophthalmologic condition.

56. The ~~method~~ use of claim 55, wherein the ophthalmologic condition is age-related macular degeneration, diabetic retinopathy, or choroidal neovascularization.

57. The ~~method~~ use of claim 56, wherein said age related macular degeneration (AMD) is wet AMD or dry AMD.

58. The ~~method~~ use of claim 33, wherein said formulation is administered to said patient one or more times.

59. The ~~method~~ use of claim 33, wherein said formulation is administered once per day, once per week, once per month, once bi-monthly, once every two months, once every three months, once every four months, once every 5 months, or once every 6 months.

60. The ~~method~~ use of claim 33, wherein said formulation is administered until one or more signs or symptoms of said angiogenesis-related disease are reduced.

61. The ~~method~~ use of claim 60, wherein said one or more signs or symptoms are reduced in severity or duration by about 2%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 90%, about 95%, or about 100%.

62. The ~~method~~ use of claim 60, wherein said one or more signs or symptoms are reduced in severity or duration by about 2-fold, about 5-fold, about 10-fold, about 15-fold, about 20-fold, about 25-fold, about 30-fold, about 35-fold, about 40-fold, about 45-fold, about 50-fold, about 55-fold, about 60-fold, about 65-fold, about 70-fold, about 75-fold, about 80-fold, about 90-fold, about 95-fold, about 100-fold or more.

63. The use of claim 60, wherein said one or more signs or symptoms are shrinking blood vessels, inhibiting endothelial cell proliferation associated with ocular disease, clearing signs or symptoms of bleeding, treating cloudy vision, providing stasis of vision loss, improving vision, and/or preventing leakage of blood vessels.

64. The ~~method~~ use of claim 33, wherein treatment results in improving the patient's condition and can be assessed by determining if one or more of the following factors has occurred: decreased cell proliferation, decreased numbers of cells, increased apoptosis, or decreased survival of at least a portion of the cells comprising the cell proliferative disorder.

65. The ~~method~~ use of claim 33, wherein treatment results in partial or total elimination of a tumor or metastases and/or prolongation of survival of the patient.

66. ~~A method of treating an ophthalmologic condition in a patient in need thereof, comprising administering to said patient~~ Use of a formulation comprising from about 1 mg/ml to about 150 mg/ml of an anti-CD105 antibody, or antigen-binding fragment thereof, up to about 100 mM buffering agent, up to about 1 M polyol, a pH of about 4.0 to about 7.5, and optionally a surfactant, whereby one or more signs or symptoms of said ophthalmologic condition are ameliorated, in the manufacture of a medicament for treating an ophthalmologic condition in a patient in need thereof.

67. The ~~method~~ use of claim 66, wherein the ophthalmologic condition is age-related macular degeneration, diabetic retinopathy, or choroidal neovascularization.

68. The ~~method~~ use of claim 67, wherein said age-related macular degeneration (AMD) is wet AMD or dry AMD.

69. The ~~method~~ use of claim 66, wherein said anti-CD105 antibody comprises a light chain variable region (V_L) having an amino acid sequence set forth as SEQ ID NO: 1; a light chain constant region (C_L) having an amino acid sequence set forth as SEQ ID NO: 2; a heavy chain variable region (V_H) having an amino acid sequence set forth as SEQ ID NO: 3; and a constant region (Fc) having an amino acid sequence set forth as SEQ ID NO: 4.

70. The ~~method~~ use of claim 66, wherein said anti-CD105 antibody comprises a V_L CDR1 having an amino acid sequence set forth as SEQ ID NO: 5; a V_L CDR2 having an amino acid sequence set forth as SEQ ID NO: 6; a V_L CDR3 having an amino acid sequence set forth as SEQ ID NO: 7; a V_H CDR1 having an amino acid sequence set forth as SEQ ID NO: 8; a V_H CDR2 having an amino acid sequence set forth as SEQ ID NO: 9; and a V_H CDR3 having an amino acid sequence set forth as SEQ ID NO: 10.

71. The ~~method~~ use of claim 66, wherein said one or more signs or symptoms are shrinking blood vessels, inhibiting endothelial cell proliferation associated with ocular disease, clearing signs or symptoms of bleeding, treating cloudy vision, providing stasis of vision loss, improving vision, and/or preventing leakage of blood vessels.

72. The ~~method~~ use of claim 66, wherein said one or more signs or symptoms are reduced in severity or duration by about 2%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 90%, about 95%, or about 100%.

73. The ~~method~~ use of claim 66, wherein said one or more signs or symptoms are reduced in severity or duration by about 2-fold, about 5-fold, about 10-fold, about 15-fold, about 20-fold, about 25-fold, about 30-fold, about 35-fold, about 40-fold, about 45-fold, about 50-fold, about 55-fold, about 60-fold, about 65-fold, about 70-fold, about 75-fold, about 80-fold, about 90-fold, about 95-fold, about 100-fold or more.

74. The ~~method~~ use of claim 66, wherein said formulation comprises less than 300 mM polyol and the formulation is made isotonic with a salt.

75. ~~A method of preventing or treating a cancer or metastasis in a subject in need thereof, comprising administering to said patient~~ Use of a formulation comprising from about 1 mg/ml to about 150 mg/ml of an anti-CD105 antibody, or antigen-binding fragment thereof, up to about 100 mM buffering agent, up to about 1 M polyol, and a pH of about 4.0 to about 7.5, whereby one or more signs or symptoms of said cancer or metastasis are ameliorated, in the manufacture of a medicament for preventing or treating a cancer or metastasis in a subject in need thereof.

76. The ~~method~~ use of claim 75, wherein said anti-CD105 antibody comprises a light chain variable region (V_L) having an amino acid sequence set forth as SEQ ID NO: 1; a light chain constant region (C_L) having an amino acid sequence set forth as SEQ ID NO: 2; a heavy chain variable region (V_H) having an amino acid sequence set forth as SEQ ID NO: 3; and a constant region (Fc) having an amino acid sequence set forth as SEQ ID NO: 4.

77. The ~~method~~ use of claim 75, wherein said anti-CD105 antibody comprises a VL CDR1 having an amino acid sequence set forth as SEQ ID NO: 5; a VL CDR2 having an amino acid sequence set forth as SEQ ID NO: 6; a VL CDR3 having an amino acid sequence set forth as SEQ ID NO: 7; a VH CDR1 having an amino acid sequence set forth as SEQ ID NO: 8; a VH CDR2 having an amino acid sequence set forth as SEQ ID NO: 9; and a VH CDR3 having an amino acid sequence set forth as SEQ ID NO: 10.

78. The ~~method~~ use of claim 75, wherein administration of the formulation prolongs the life of the subject.

79. The ~~method~~ use of claim 75, wherein said cancer is a primary tumor or a metastatic tumor.

80. The ~~method~~ use of claim 75, wherein said cancer is a solid tumor.

81. The ~~method~~ use of claim 80, wherein said solid tumor is of a tissue or organ selected from among skin, melanoma, lung, pancreas, breast, ovary, colon, rectum, stomach, thyroid, laryngeal, ovarian, prostate, colorectal, head, neck, eye, mouth, throat, esophagus, chest, bone, testicular, lymphoid, marrow, bone, sarcoma, renal, sweat gland, liver, kidney, brain (*e.g.* glioblastoma multiforme, glioma), and the like.

82. The ~~method~~ use of claim 81, wherein said solid tumor is a colon tumor, a breast tumor, a kidney tumor, a lung tumor, a prostate tumor, an ovarian tumor, or a metastasis of any of such tumors.

83. The ~~method~~ use of claim 75, wherein treatment results in improving the subject's condition and can be assessed by determining if one or more of the following factors has occurred: decreased cell proliferation, decreased numbers of cells, increased apoptosis, or decreased survival of at least a portion of the cells comprising the cell proliferative disorder.

84. The ~~method~~ use of claim 75, wherein treatment results in partial or total elimination of a tumor or metastases and/or prolongation of survival of the patient.

85. The ~~method~~ use of claim 75, wherein said one or more signs or symptoms are reduced in severity or duration by about 2%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 90%, about 95%, or about 100%.

86. The ~~method~~ use of claim 75, wherein said one or more signs or symptoms are reduced in severity or duration by about 2-fold, about 5-fold, about 10-fold, about 15-fold, about 20-fold, about 25-fold, about 30-fold, about 35-fold, about 40-fold, about 45-fold, about 50-fold, about 55-fold, about 60-fold, about 65-fold, about 70-fold, about 75-fold, about 80-fold, about 90-fold, about 95-fold, about 100-fold or more.

87. The ~~method~~ use of claim 75, comprising about 25 mg/ml anti-CD105 antibody or, antigen-binding fragment thereof.

88. The ~~method~~ use of claim 75, comprising about 50 mg/ml anti-CD105 antibody or, antigen-binding fragment thereof.

89. The ~~method~~ use of claim 75, comprising about 100 mg/ml anti-CD105 antibody or, antigen-binding fragment thereof.

90. The ~~method~~ use of claim 75, wherein said buffering agent is histidine or acetate.

91. The ~~method~~ use of claim 90, comprising about 20 mM histidine or acetate.

92. The ~~method~~ use of claim 75, wherein the polyol is a sugar.

93. The ~~method~~ use of claim 92, wherein said sugar is a non-reducing sugar.

94. The ~~method~~ use of claim 93, wherein the non-reducing sugar is trehalose or sucrose.

95. The ~~method~~ use of claim 94, comprising about 240 mM trehalose or sucrose.

96. The ~~method~~ use of claim 92, wherein said sugar is sorbitol.

97. The ~~method~~ use of claim 96, comprising about 240 mM sorbitol.

98. The ~~method~~ use of claim 75, wherein said formulation comprises less than 300 mM polyol and the formulation is made isotonic with a salt.

99. The ~~method~~ use of claim 75, further comprising a surfactant.

100. The ~~method~~ use of claim 99, wherein the surfactant is polysorbate 20, polysorbate 80 or Pluronic® F68.

101. The ~~method~~ use of claim 75, wherein said formulation is administered intravenously.

102. A formulation comprising any one of the formulations 1-39 of Table 1.

103. A pre-filled syringe comprising a formulation of claim 102.

104. Use of a formulation of claim 102 for the treatment of an angiogenesis-related disease.

105. Use of a formulation of claim 102 in the manufacture of a medicament for the treatment of an angiogenesis-related disease.